Miguel H Vicco1, Franco Ferini2, Luz Rodeles2, Paula Cardona3, Iván Bontempi3, Susana Lioi4, Juan Beloscar5, Takeshi Nara6, Iván Marcipar3, Oscar A Bottasso7. 1. Laboratorio de Tecnología Inmunológica, Facultad de Bioquímica y Ciencias Biológicas, Universidad Nacional del Litoral, Santa Fe, Argentina; Servicio de Clínica Médica, Hospital J.B. Iturraspe, Santa Fe, Argentina. Electronic address: mvicco@santafe-conicet.gov.ar. 2. Servicio de Clínica Médica, Hospital J.B. Iturraspe, Santa Fe, Argentina. 3. Laboratorio de Tecnología Inmunológica, Facultad de Bioquímica y Ciencias Biológicas, Universidad Nacional del Litoral, Santa Fe, Argentina. 4. Cátedra de Química Analítica Clínica, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Santa Fe, Argentina. 5. Servicio de Cardiología, Hospital Provincial del Centenario, Carrera de Especialización en Cardiología, Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Santa Fe, Argentina. 6. Departamento de Parasitología Celular y Molecular, Escuela de Medicina, Universidad de Juntendo, Tokyo, Japan. 7. Instituto de Inmunología, Facultad de Medicina, Universidad Nacional de Rosario, Santa Fe, Argentina.
Abstract
INTRODUCTION AND OBJECTIVES: Trypanosoma cruzi infection has been shown to induce humoral autoimmune responses against host antigens tissues. Particularly, antibodies cross-reacting with myocardial antigens may play a role in the development of the severe forms of chronic Chagas disease. The aim of this study was to determine the association between clinical stage of the disease and the presence of autoantibodies in patients with chronic Chagasic disease. METHODS: We performed a cross-sectional study in T. cruzi-seropositive patients divided into 3 groups according to the classic classification of chronic Chagas heart of Storino et al. All participants underwent complete clinical examination and their sera were used to measure autoantibody levels. RESULTS: All patients had detectable levels of anti-p2β and anti-B13 autoantibodies but none had anti-Na-K-ATPase antibodies. No association was observed between electrocardiographic conduction disturbances and autoantibody levels. Patients with chronic Chagas disease stage III had the highest levels of anti-B13 antibodies and a high risk of mortality score, showing a clear association between disease stage and this score. CONCLUSIONS: Anti-B13 antibodies were significantly higher in chronic Chagas disease stage III patients, suggesting that these antibodies may be involved in disease progression and that they might be a useful marker of poor prognosis in terms of heart compromise. Our results also reveal an important correlation between the level of anti-B13 autoantibodies and symptomatic heart failure and/or dilated cardiomyopathy.
INTRODUCTION AND OBJECTIVES:Trypanosoma cruzi infection has been shown to induce humoral autoimmune responses against host antigens tissues. Particularly, antibodies cross-reacting with myocardial antigens may play a role in the development of the severe forms of chronic Chagas disease. The aim of this study was to determine the association between clinical stage of the disease and the presence of autoantibodies in patients with chronic Chagasic disease. METHODS: We performed a cross-sectional study in T. cruzi-seropositive patients divided into 3 groups according to the classic classification of chronic Chagas heart of Storino et al. All participants underwent complete clinical examination and their sera were used to measure autoantibody levels. RESULTS: All patients had detectable levels of anti-p2β and anti-B13 autoantibodies but none had anti-Na-K-ATPase antibodies. No association was observed between electrocardiographic conduction disturbances and autoantibody levels. Patients with chronic Chagas disease stage III had the highest levels of anti-B13 antibodies and a high risk of mortality score, showing a clear association between disease stage and this score. CONCLUSIONS: Anti-B13 antibodies were significantly higher in chronic Chagas disease stage III patients, suggesting that these antibodies may be involved in disease progression and that they might be a useful marker of poor prognosis in terms of heart compromise. Our results also reveal an important correlation between the level of anti-B13 autoantibodies and symptomatic heart failure and/or dilated cardiomyopathy.
Keywords:
Anti-B13 autoantibodies; Autoanticuerpos anti-B13; CCD; Chagas disease; Enfermedad de Chagas; Heart failure; IODN; Insuficiencia cardiaca; Trypanosoma cruzi; chronic Chagas disease; index of the optical density of autoantibodies in relation to the negative control
Authors: Maria C Guimaro; Rozeneide M Alves; Ester Rose; Alessandro O Sousa; Ana de Cássia Rosa; Mariana M Hecht; Marcelo V Sousa; Rafael R Andrade; Tamires Vital; Jiří Plachy; Nadjar Nitz; Jiří Hejnar; Clever C Gomes; Antonio R L Teixeira Journal: PLoS Negl Trop Dis Date: 2014-12-18
Authors: Esteban R Fernández; Gabriela C Olivera; Luz P Quebrada Palacio; Mariela N González; Yolanda Hernandez-Vasquez; Natalia María Sirena; María L Morán; Oscar S Ledesma Patiño; Miriam Postan Journal: PLoS One Date: 2014-08-11 Impact factor: 3.240